Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...

Related Keywords

Chicago ,Illinois ,United States ,Philadelphia ,Pennsylvania ,American ,Davendra Sohal ,Shveta Dighe ,Eugenep Kennedy ,Drug Administration ,Nasdaq ,Carisma Therapeutics Inc ,American Society Of Clinical Oncology ,Company Annual Report On Form ,University Of Cincinnati Cancer Center ,Exchange Commission ,Carisma Therapeutics ,Chief Medical Officer ,Cincinnati Cancer ,American Society ,Clinical Oncology ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,